Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

If you have been watching Sarepta Therapeutics (SRPT), this week's headlines have probably caught your eye. Multiple law firms have announced class action lawsuits against the company, following ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

Elevidys is an adeno-associated virus vector-based gene therapy using Sarepta Therapeutics, Inc.'s AAVrh74 Platform Technology for the treatment of Duchenne muscular dystrophy.

After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without ...

Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...

Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, sending the company's shares 59% higher in extended trading.

Sarepta Therapeutics, Inc. (SRPT) announced on Thursday that it has entered into agreements with investors to restructure ...

Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology - Results at one year demonstrate continued ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about liquidity and the ...

Sarepta’s strategic partnerships, including collaborations with Nationwide, Lacerta, and Lysogene for gene therapy programs, may help the company maintain its competitive edge.

Despite rocky road with its DMD gene therapy, Sarepta Therapeutics hands in $30 million to Lacerta in exchange for a group of CNC therapies.